A lack of ER expression in CTCs from patients with ER-positive primary breast cancer has been previously reported [30, 31] The presence of ER-negative CTCs in ER-positive cancer patients is significant as these CTCs may escape ER-targeted therapies, conferring selection pressure for their survival. This evidence concerns the gene ESR1 and breast carcinoma.